HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

Benzinga · 3d ago
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.